ACADIA Pharmaceuticals Announces Executive Appointments to Lead Medical Affairs and Science

-Robert Kaper, M.D., named Senior Vice President, Global Head ofMedical Affairs

-Eliseo Salinas, M.D., M.Sc., named Senior Vice President, ChiefScientific Officer and Head of External Innovation

SAN DIEGO—(BUSINESS WIRE)—Sep. 26, 2018—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesto address unmet medical needs in central nervous system (CNS)disorders, today announced two executive appointments: Robert Kaper,M.D., has joined ACADIA as Senior Vice President, Global Head of MedicalAffairs, and Eliseo Salinas, M.D., M.Sc., has joined the company asSenior Vice President, Chief Scientific Officer and Head of ExternalInnovation. In these newly created roles, Dr. Kaper will report to SteveDavis, ACADIA’s President and Chief Executive Officer, and Dr. Salinaswill report to Serge Stankovic, M.D., M.S.P.H., Executive Vice Presidentand Head of Research and Development.

“We are excited to welcome Rob Kaper and Eliseo Salinas to the ACADIAteam,” said Steve Davis. “Rob brings 25 years of experience across allfunctions in global medical affairs and pharmacovigilance. Eliseo has astellar track record in leading several R&D organizations and providingthe strategic and operational guidance to bring to market 15pharmaceuticals in various therapeutic areas, including CNS. Both Roband Eliseo will be of tremendous help to us as we continue to realizethe significant opportunities of NUPLAZID and deliver on our vision ofbuilding a leading CNS company.”

Dr. Kaper most recently served as Senior Vice President of Medical andScientific Affairs for AMAG Pharmaceuticals where he led medical affairsand pharmacovigilance for marketed products, new indications and newassets. Throughout his career, Dr. Kaper has built successful teams tosupport strategic planning and execution of late stage development, newproduct launches and lifecycle management. His previous leadershippositions include Vice President, Global Medical Affairs for Teva andVice President, Medical Affairs for Cephalon and Organon. Dr. Kaperreceived his M.D. from the Free University of Amsterdam and completedhis post-graduate training in neurosurgery and orthopedic surgery atAmsterdam-based hospitals.

Dr. Salinas joins ACADIA from New World Laboratories where he was ChiefMedical Officer and led pre-clinical, clinical and regulatory activitiesfor directly reprogrammed cell therapy programs in neurodegeneration.Dr. Salinas has 27 years of experience developing diverse therapeuticproducts for CNS and other disorders and has been directly involved with16 investigational new drug (IND) submissions and 15 regulatoryapprovals. Prior to New World Laboratories, Dr. Salinas held leadershippositions in R&D at several companies including Executive VicePresident, R&D and Chief Scientific Officer at Shire; Executive VicePresident, Head of Development and Chief Medical Officer at ElanPharmaceuticals; Vice President, Head of Worldwide CNS ProductDevelopment at Wyeth and Head of R&D at several small pharmaceutical andbiotechnology companies. Dr. Salinas received his M.D. from theUniversity of Buenos Aires, completed his residency in Psychiatry at theClinique des Maladies Mentales et de l'Encéphale, Paris and obtained hisMaster’s degree in Pharmacology from the Université Pierre et MarieCurie, Academie de Paris.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders. ACADIA has developed and iscommercializing the first and only medicine approved for the treatmentof hallucinations and delusions associated with Parkinson’s diseasepsychosis. In addition, ACADIA has ongoing clinical development effortsin additional areas with significant unmet need, includingdementia-related psychosis, schizophrenia inadequate response,schizophrenia-negative symptoms, major depressive disorder and Rettsyndrome. This press release and further information about ACADIA can befound at: www.acadia-pharm.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the benefits to be derived fromNUPLAZID. These statements are only predictions based on currentinformation and expectations and involve a number of risks anduncertainties. Actual events or results may differ materially from thoseprojected in any of such statements due to various factors, includingthe risks and uncertainties inherent in drug discovery, development,approval and commercialization. For a discussion of these and otherfactors, please refer to ACADIA’s annual report on Form 10-K for theyear ended December 31, 2017 as well as ACADIA’s subsequent filings withthe Securities and Exchange Commission. You are cautioned not to placeundue reliance on these forward-looking statements, which speak only asof the date hereof. This caution is made under the safe harborprovisions of the Private Securities Litigation Reform Act of 1995. Allforward-looking statements are qualified in their entirety by thiscautionary statement and ACADIA undertakes no obligation to revise orupdate this press release to reflect events or circumstances after thedate hereof, except as required by law.

Important Safety Information and Indication for NUPLAZID(pimavanserin)

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITHDEMENTIA-RELATED PSYCHOSIS
Elderly patients withdementia-related psychosis treated with antipsychotic drugs are at anincreased risk of death. NUPLAZID is not approved for the treatment ofpatients with dementia-related psychosis unrelated to the hallucinationsand delusions associated with Parkinson’s disease psychosis.

NUPLAZID is an atypical antipsychotic indicated for the treatment ofhallucinations and delusions associated with Parkinson’s diseasepsychosis.

Contraindication: NUPLAZID is contraindicated in patients with a historyof a hypersensitivity reaction to pimavanserin or any of its components.Rash, urticaria, and reactions consistent with angioedema (e.g., tongueswelling, circumoral edema, throat tightness, and dyspnea) have beenreported.

QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use ofNUPLAZID should be avoided in patients with known QT prolongation or incombination with other drugs known to prolong QT interval includingClass 1A antiarrhythmics or Class 3 antiarrhythmics, certainantipsychotic medications, and certain antibiotics. NUPLAZID should alsobe avoided in patients with a history of cardiac arrhythmias, as well asother circumstances that may increase the risk of the occurrence oftorsade de pointes and/or sudden death, including symptomaticbradycardia, hypokalemia or hypomagnesemia, and presence of congenitalprolongation of the QT interval.

Adverse Reactions: The most common adverse reactions (≥2% for NUPLAZIDand greater than placebo) were peripheral edema (7% vs 2%), nausea (7%vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%),constipation (4% vs 3%), and gait disturbance (2% vs <1%).

Drug Interactions: Coadministration with strong CYP3A4 inhibitors (e.g.,ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mgtaken orally as one tablet once daily. Coadministration with strongCYP3A4 inducers may reduce NUPLAZID exposure. Monitor patients forreduced efficacy and an increase in NUPLAZID dosage may be needed.

Pediatric Use: Safety and efficacy have not been established inpediatric patients.

Dosage and Administration: Recommended dose: 34 mg taken orally oncedaily, without titration.

NUPLAZID is available as 34 mg capsules, 17 mg tablets and 10 mg tablets.

For additional Important Safety Information, including Boxed WARNING,please see the full Prescribing Information for NUPLAZID at https://www.NUPLAZID.com/pdf/NUPLAZID_Prescribing_Information.pdf

Source: ACADIA Pharmaceuticals Inc.

Investor Contact:

ACADIA Pharmaceuticals Inc.
ElenaRidloff, CFA
(858) 558-2871
ir@acadia-pharm.com
or
MediaContact:
Taft Communications
Bob Laverty
(609)558-5570
bob@taftcommunications.com